21.89
price up icon1.53%   0.33
after-market Dopo l'orario di chiusura: 21.89
loading
Precedente Chiudi:
$21.56
Aprire:
$22.035
Volume 24 ore:
191.65K
Relative Volume:
0.60
Capitalizzazione di mercato:
$748.91M
Reddito:
-
Utile/perdita netta:
$-81.05M
Rapporto P/E:
-8.3448
EPS:
-2.6232
Flusso di cassa netto:
$-68.97M
1 W Prestazione:
-0.05%
1M Prestazione:
-3.99%
6M Prestazione:
-19.67%
1 anno Prestazione:
+7.15%
Intervallo 1D:
Value
$21.68
$22.10
Intervallo di 1 settimana:
Value
$21.10
$23.38
Portata 52W:
Value
$15.47
$36.37

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name
Nome
Arrivent Biopharma Inc
Name
Telefono
240-780-6356
Name
Indirizzo
18 CAMPUS BLVD., NEWTOWN SQUARE
Name
Dipendente
52
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
AVBP's Discussions on Twitter

Confronta AVBP con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
AVBP
Arrivent Biopharma Inc
21.89 791.15M 0 -81.05M -68.97M -2.6232
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-10 Ripresa Goldman Buy
2025-03-20 Iniziato B. Riley Securities Buy
2025-03-10 Iniziato Guggenheim Buy
2024-07-22 Iniziato Oppenheimer Outperform
2024-04-30 Iniziato H.C. Wainwright Buy
2024-02-20 Iniziato Citigroup Buy
2024-02-20 Iniziato Goldman Buy
2024-02-20 Iniziato Jefferies Buy
Mostra tutto

Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie

pulisher
04:00 AM

ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data - MyChesCo

04:00 AM
pulisher
Jul 22, 2025

ArriVent BioPharma Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is ArriVent BioPharma Inc. a good long term investmentOverwhelming financial success - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada

Jul 22, 2025
pulisher
Jul 22, 2025

What drives ArriVent BioPharma Inc. stock priceAccelerated wealth expansion - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about ArriVent BioPharma Inc. stockFree AI-Backed Trading Signals - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What makes ArriVent BioPharma Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser

Jul 22, 2025
pulisher
Jul 21, 2025

ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating By Investing.com - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

ArriVent Biopharma announces data from its FURVENT Phase 3 study - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

ArriVent expects topline data from lung cancer drug trial in early 2026 By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - The Manila Times

Jul 21, 2025
pulisher
Jul 21, 2025

New Strong Sell Stocks For July 21st - Barchart.com

Jul 21, 2025
pulisher
Jul 21, 2025

New Strong Sell Stocks for July 21st - The Globe and Mail

Jul 21, 2025
pulisher
Jul 18, 2025

Is ArriVent BioPharma Inc. stock a growth or value playDaily Price Surge List - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

P 500Low Risk Trade Timing Signals - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

60 Degrees Pharmaceuticals Secures $5 Million in Public Offering - AInvest

Jul 16, 2025
pulisher
Jul 15, 2025

Why ArriVent BioPharma Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

ArriVent BioPharma Conducts $75 Million Public Offering - Global Legal Chronicle

Jul 14, 2025
pulisher
Jul 12, 2025

ArriVent BioPharma (NASDAQ:AVBP) Given a $33.00 Price Target by The Goldman Sachs Group Analysts - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

The Goldman Sachs Group Reiterates “Buy” Rating for ArriVent BioPharma (NASDAQ:AVBP) - Defense World

Jul 12, 2025
pulisher
Jul 10, 2025

How To Trade (AVBP) - news.stocktradersdaily.com

Jul 10, 2025
pulisher
Jul 10, 2025

ArriVent BioPharma stock rating resumed at Buy by Goldman Sachs - Investing.com Canada

Jul 10, 2025
pulisher
Jul 08, 2025

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering - Mintz

Jul 08, 2025
pulisher
Jul 03, 2025

ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval - Investing.com Canada

Jul 03, 2025
pulisher
Jul 03, 2025

ArriVent BioPharma Announces $75 Million Public Offering - The Globe and Mail

Jul 03, 2025
pulisher
Jul 02, 2025

Latham & Watkins Advises on ArriVent’s US$75 Million Common Stock Offering and Pre-Funded Warrants - Latham & Watkins LLP

Jul 02, 2025
pulisher
Jul 02, 2025

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

Jul 02, 2025
pulisher
Jul 01, 2025

ArriVent BioPharma Plans $75 Million Public Offering - MarketScreener

Jul 01, 2025
pulisher
Jul 01, 2025

ArriVent BioPharma announces $75 million public offering By Investing.com - Investing.com UK

Jul 01, 2025
pulisher
Jul 01, 2025

ArriVent BioPharma's $75M Offering: Navigating Dilution for Oncology's Next Breakthrough - AInvest

Jul 01, 2025
pulisher
Jun 28, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Buy” by Brokerages - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

Research Analysts Offer Predictions for AVBP FY2025 Earnings - Defense World

Jun 27, 2025
pulisher
Jun 25, 2025

ArriVent BioPharma (NASDAQ:AVBP) Given Buy Rating at Guggenheim - Defense World

Jun 25, 2025
pulisher
Jun 24, 2025

Latest Analyst Updates: June 24th, 2025 - The Globe and Mail

Jun 24, 2025
pulisher
Jun 24, 2025

Clear Street initiates ArriVent BioPharma stock with Buy rating By Investing.com - Investing.com Canada

Jun 24, 2025
pulisher
Jun 23, 2025

Citi ups ArriVent price target to $40, adding ‘upside 90-day short-term view’ - TipRanks

Jun 23, 2025
pulisher
Jun 23, 2025

ArriVent BioPharma (AVBP) Presents Promising Firmonertinib Data in Lung Cancer Study | AVBP Stock News - GuruFocus

Jun 23, 2025
pulisher
Jun 23, 2025

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study - The Manila Times

Jun 23, 2025
pulisher
Jun 20, 2025

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC - The Manila Times

Jun 20, 2025
pulisher
Jun 20, 2025

ArriVent to Unveil Next Steps for Breakthrough EGFR PACC Lung Cancer Drug Firmonertinib - Stock Titan

Jun 20, 2025
pulisher
Jun 13, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases New Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Jun 13, 2025

Arrivent Biopharma Inc Azioni (AVBP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):